Literature DB >> 22895082

Lactic acid production by Streptococcus thermophilus alters Clostridium difficile infection and in vitro Toxin A production.

Glynis L Kolling1, Martin Wu, Cirle A Warren, Evelyn Durmaz, Todd R Klaenhammer, Michael P Timko, Richard L Guerrant.   

Abstract

Antibiotic treatment to treat specific infections has the potential to effectively target the offending microbe as well as other microbes that colonize sites within a host. Antibiotic-associated diarrhea (AAD) is a classic example resulting from disruption of host microbial communities; 20% of patients with AAD are likely to become colonized with Clostridium difficile. Restoration of a "normal" microbial community within the host using probiotic bacteria is one approach to circumvent AAD and C. difficile infection. The goals of this study were to assess the interactions between Streptococcus thermophilus, a potential probiotic organism and C. difficile using both in vitro and in vivo systems. Exposure of C. difficile to filtered supernatants from S. thermophilus showed a dose-dependent, bactericidal effect due to lactic acid. Additional studies show that levels of lactic acid (10 mM) that did not inhibit bacterial growth had the potential to decrease tcdA expression and TcdA release into the extracellular milieu. In vivo, treatment with viable S. thermophilus significantly increased luminal levels of lactate in the cecum compared with UV-irradiated S. thermophilus. In the context of infection with C. difficile, mice treated with viable S. thermophilus exhibited 46% less weight loss compared with untreated controls; moreover, less pathology, diarrhea, and lower detectable toxin levels in cecal contents were evident more often in S. thermophillus treated mice. A significant, inverse correlation (Spearman r = -0.942, p = 0.017) between the levels of luminal lactate and abundance of C. difficile were noted suggesting that lactate produced by S. thermophilus is a factor impacting the progression of C. difficile infection in the murine system.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895082      PMCID: PMC3495789          DOI: 10.4161/gmic.21757

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  23 in total

1.  Impact of the metabolic activity of Streptococcus thermophilus on the colon epithelium of gnotobiotic rats.

Authors:  Françoise Rul; Leila Ben-Yahia; Fatima Chegdani; Laura Wrzosek; Stéphane Thomas; Marie-Louise Noordine; Christophe Gitton; Claire Cherbuy; Philippe Langella; Muriel Thomas
Journal:  J Biol Chem       Date:  2011-01-14       Impact factor: 5.157

2.  Real-time multiplex polymerase chain reaction assay for rapid detection of Clostridium difficile toxin-encoding strains.

Authors:  Beth A Houser; Arthur L Hattel; Bhushan M Jayarao
Journal:  Foodborne Pathog Dis       Date:  2010-06       Impact factor: 3.171

3.  Co-culture with potentially probiotic microorganisms antagonises virulence factors of Clostridium difficile in vitro.

Authors:  Fernando M Trejo; Pablo F Pérez; Graciela L De Antoni
Journal:  Antonie Van Leeuwenhoek       Date:  2010-03-16       Impact factor: 2.271

4.  Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria.

Authors:  G Corthier; F Dubos; P Raibaud
Journal:  Appl Environ Microbiol       Date:  1985-01       Impact factor: 4.792

5.  The inhibitory spectrum of thermophilin 9 from Streptococcus thermophilus LMD-9 depends on the production of multiple peptides and the activity of BlpG(St), a thiol-disulfide oxidase.

Authors:  Laetitia Fontaine; Pascal Hols
Journal:  Appl Environ Microbiol       Date:  2007-12-21       Impact factor: 4.792

6.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

Authors:  L V McFarland; C M Surawicz; R N Greenberg; R Fekety; G W Elmer; K A Moyer; S A Melcher; K E Bowen; J L Cox; Z Noorani
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

7.  Inhibition of Clostridium difficile strains by intestinal Lactobacillus species.

Authors:  Paul Naaber; Imbi Smidt; Jelena Štšepetova; Tatjana Brilene; Heidi Annuk; Marika Mikelsaar
Journal:  J Med Microbiol       Date:  2004-06       Impact factor: 2.472

8.  Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial.

Authors:  Mary Hickson; Aloysius L D'Souza; Nirmala Muthu; Thomas R Rogers; Susan Want; Chakravarthi Rajkumar; Christopher J Bulpitt
Journal:  BMJ       Date:  2007-06-29

9.  A 6 x 6 drop plate method for simultaneous colony counting and MPN enumeration of Campylobacter jejuni, Listeria monocytogenes, and Escherichia coli.

Authors:  Chin Yi Chen; Gary W Nace; Peter L Irwin
Journal:  J Microbiol Methods       Date:  2003-11       Impact factor: 2.363

10.  Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation.

Authors:  Dionysios A Antonopoulos; Susan M Huse; Hilary G Morrison; Thomas M Schmidt; Mitchell L Sogin; Vincent B Young
Journal:  Infect Immun       Date:  2009-03-23       Impact factor: 3.441

View more
  14 in total

Review 1.  Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection.

Authors:  L Patrick Schenck; Paul L Beck; Justin A MacDonald
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

2.  Potential of Omega-3 Polyunsaturated Fatty Acids in Managing Chemotherapy- or Radiotherapy-Related Intestinal Microbial Dysbiosis.

Authors:  Yue Zhang; Boyan Zhang; Lihua Dong; Pengyu Chang
Journal:  Adv Nutr       Date:  2019-01-01       Impact factor: 8.701

3.  Characterization of bacterial isolates from the microbiota of mothers' breast milk and their infants.

Authors:  Kimberly Kozak; Duane Charbonneau; Rosemary Sanozky-Dawes; Todd Klaenhammer
Journal:  Gut Microbes       Date:  2015

4.  Zinc deficiency alters host response and pathogen virulence in a mouse model of enteroaggregative Escherichia coli-induced diarrhea.

Authors:  David T Bolick; Glynis L Kolling; John H Moore; Luís Antônio de Oliveira; Kenneth Tung; Casandra Philipson; Monica Viladomiu; Raquel Hontecillas; Josep Bassaganya-Riera; Richard L Guerrant
Journal:  Gut Microbes       Date:  2014

5.  Secreted Compounds of the Probiotic Bacillus clausii Strain O/C Inhibit the Cytotoxic Effects Induced by Clostridium difficile and Bacillus cereus Toxins.

Authors:  Gabrielle Ripert; Silvia M Racedo; Anne-Marie Elie; Claudine Jacquot; Philippe Bressollier; Maria C Urdaci
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

6.  Effect of Bifidobacterium upon Clostridium difficile Growth and Toxicity When Co-cultured in Different Prebiotic Substrates.

Authors:  L Valdés-Varela; Ana M Hernández-Barranco; Patricia Ruas-Madiedo; Miguel Gueimonde
Journal:  Front Microbiol       Date:  2016-05-18       Impact factor: 5.640

Review 7.  Protective Microbiota: From Localized to Long-Reaching Co-Immunity.

Authors:  Lynn Chiu; Thomas Bazin; Marie-Elise Truchetet; Thierry Schaeverbeke; Laurence Delhaes; Thomas Pradeu
Journal:  Front Immunol       Date:  2017-12-07       Impact factor: 7.561

8.  Sulfites inhibit the growth of four species of beneficial gut bacteria at concentrations regarded as safe for food.

Authors:  Sally V Irwin; Peter Fisher; Emily Graham; Ashley Malek; Adriel Robidoux
Journal:  PLoS One       Date:  2017-10-18       Impact factor: 3.240

9.  Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection.

Authors:  Shanlin Ke; Nira R Pollock; Xu-Wen Wang; Xinhua Chen; Kaitlyn Daugherty; Qianyun Lin; Hua Xu; Kevin W Garey; Anne J Gonzales-Luna; Ciarán P Kelly; Yang-Yu Liu
Journal:  Gut Microbes       Date:  2021 Jan-Dec

10.  Screening of Bifidobacteria and Lactobacilli Able to Antagonize the Cytotoxic Effect of Clostridium difficile upon Intestinal Epithelial HT29 Monolayer.

Authors:  Lorena Valdés-Varela; Marta Alonso-Guervos; Olivia García-Suárez; Miguel Gueimonde; Patricia Ruas-Madiedo
Journal:  Front Microbiol       Date:  2016-04-22       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.